New treatment approach for Stargardt disease
Polypharmacological approach to treatment of Stargardt disease
This study is exploring a new way to help people with Stargardt disease by testing a treatment that could protect their eyesight by reducing harmful substances in the eye.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11044985 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment for Stargardt disease, a genetic condition that leads to vision loss. The approach aims to reduce the harmful substances that accumulate in the retina by partially inhibiting a key enzyme involved in the visual cycle. By targeting this enzyme, the researchers hope to prolong the survival of retinal cells and improve vision outcomes for patients. The study will involve testing this method in laboratory models to assess its effectiveness and safety.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Stargardt disease, particularly those with mutations in the ABCA4 gene.
Not a fit: Patients with other forms of macular degeneration or those without genetic mutations associated with Stargardt disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel treatment that slows down or prevents vision loss in patients with Stargardt disease.
How similar studies have performed: Previous research has shown promise in targeting the visual cycle for similar retinal diseases, indicating potential for success in this novel approach.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Petrukhin, Konstantin — Columbia University Health Sciences
- Study coordinator: Petrukhin, Konstantin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.